12:01 PM
 | 
Dec 06, 2018
 |  BC Extra  |  Clinical News

Conatus down on Phase IIb NASH miss

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) lost $2.56 (57%) to $1.94 on Thursday after it said all three doses of emricasan missed the primary endpoint of improving mean hepatic venous pressure gradient (HVPG) from baseline to week 24 vs. placebo in the Phase IIb ENCORE-PH trial to treat non-alcoholic steatohepatitis.

The double-blind, international trial enrolled 263 patients with compensated or early decompensated liver cirrhosis and severe portal hypertension to receive placebo or twice-daily 5, 25 or 50 mg oral emricasan for 24 weeks. Data from a six-month extension of ENCORE-PH are expected in mid-2019.

Emricasan is also in Phase IIb testing for NASH fibrosis, with data expected in 1H19, and for decompensated NASH cirrhosis, with data expected in mid-2019.

Novartis AG (SIX:NOVN; NYSE:NVS) has exclusive, worldwide rights to the pan-caspase protease inhibitor from Conatus.

Conatus announced the news on Wednesday when U.S. markets were closed.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD